Regulation of thrombin generation by TFPI in plasma without and with heparin

Translational Research

Volumn 153, Issue 3, 2009, Pages 124-131

  Brodin, Ellen ^a   Appelbom, Hege ^a   Østerud, Bjarne ^a   Hilden, Ida ^a   Petersen, Lars C ^a   Hansen, John Bjarne ^a  

^a Center for Heart Failure Research   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CALIBRATED AUTOMATED THROMBOGRAPHY; CELL STRAIN BHK; ESCHERICHIA COLI; GLYCOSYLATION; HEMATOLOGICAL PROCEDURES; HUMAN; MALE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL;

EID: 59849127980     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.12.004     Document Type: Article

References (37)

1. Rapaport S.I., and Rao L.V. The tissue factor pathway: how it has become a "prima ballerina.". Thromb Haemost 74 (1995) 7-17
2. Broze Jr. G.J., and Miletich J.P. Characterization of the inhibition of tissue factor in serum. Blood 69 (1987) 150-155
3. Rao L.V., and Rapaport S.I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69 (1987) 645-651
4. Abumiya T., Enjyoji K., Kokawa T., Kamikubo Y., and Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 118 (1995) 178-182
5. Wesselschmidt R., Likert K., Girard T., Wun T.C., and Broze Jr. G.J. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 79 (1992) 2004-2010
6. Sandset P.M., and Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 78 (1997) 467-470
7. Broze Jr. G.J., Lange G.W., Duffin K.L., and MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 5 (1994) 551-559
8. Nordfang O., Bjorn S.E., Valentin S., et al. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 30 (1991) 10371-10376
9. Bourin M.C., and Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 289 (1993) 313-330
10. Sandset P.M., Abildgaard U., and Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50 (1988) 803-813
11. Harenberg J., Siegele M., Dempfle C.E., Stehle G., and Heene D.L. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemost 70 (1993) 942-945
12. Mannhalter C., and Quehenberger P. Laboratory methods in the haemostatic laboratory. Thromb Haemost 96 (2006) 545-546
13. Hemker H.C., Giesen P., AlDieri R., et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 32 (2002) 249-253
14. Kasper C.K., Aledort L., Aronson D., et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34 (1975) 612
15. Sandset P.M., Larsen M.L., Abildgaard U., Lindahl A.K., and Odegaard O.R. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 2 (1991) 425-433
16. Ostergaard P., Nordfang O., Petersen L.C., Valentin S., and Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations. Haemostasis 23 (1993) 107-111
17. Callander N.S., Rao L.V., Nordfang O., Sandset P.M., Warn-Cramer B., and Rapaport S.I. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem 267 (1992) 876-882
18. Veer C., and Mann K.G. Regulation of tissue factor initiated Thrombin Generation by the stoichiometric inhibitors tissue factor pathway inhibitor, Antithrombin-III, and Heparin Cofactor-II. J Biol Chem 272 (1997) 4367-4377
19. Hockin M.F., Jones K.C., Everse S.J., and Mann K.G. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 277 (2002) 18322-18333
20. Warn-Cramer B.J., and Maki S.L. Purification of tissue factor pathway inhibitor (TFPI) from rabbit plasma and characterization of its differences from TFPI isolated from human plasma. Thromb Res 67 (1992) 367-383
21. Novotny W.F., Girard T.J., Miletich J.P., and Broze Jr. G.J. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264 (1989) 18832-18837
22. Hansen J.B., Huseby K.R., Huseby N.E., Ezban M., and Nordoy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res 85 (1997) 413-425
23. Wun T.C., Kretzmer K.K., Palmier M.O., et al. Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb Haemost 68 (1992) 54-59
24. Nordøy A. Difference in the heparin-neutralizing effect of protamine and polybrene as tested by thrombotest. Scand J Clin Lab Invest 15 (1963) 205-210
25. Lindahl A.K., Abildgaard U., and Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 64 (1991) 155-168
26. Wun T.C. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 79 (1992) 430-438
27. Valentin S., Ostergaard P., Kristensen H., and Nordfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coagul Fibrinolysis 3 (1992) 221-222
28. Broze Jr. G.J., Wesselschmidt R., Higuchi D., et al. The interaction between LACI and heparin. Adv Exp Med Biol 313 (1992) 189-197
29. Huang Z.F., Wun T.C., and Broze Jr. G.J. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 268 (1993) 26950-26955
30. Jesty J., Lorenz A., Rodriguez J., and Wun T.C. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood 87 (1996) 2301-2307
31. Petersen L.C., Bjorn S.E., and Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 67 (1992) 537-541
32. Rao L.V., Rapaport S.I., and Hoang A.D. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 81 (1993) 2600-2607
33. Lawson J.H., Butenas S., Ribarik N., and Mann K.G. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 268 (1993) 767-770
34. Rao L.V., Nordfang O., Hoang A.D., and Pendurthi U.R. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 85 (1995) 121-129
35. Marciniak E. Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 24 (1973) 391-400
36. Rosenberg R.D., and Rosenberg J.S. Natural anticoagulant mechanisms. J Clin Invest 74 (1984) 1-6
37. Ardissino D., Merlini P.A., Bauer K.A., et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 102 (2003) 2731-2735